BRIEF-BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO)

Reuters
31 Mar
BRIEF-BiomX Announces Positive Topline Results From Phase 2 Trial Evaluating Bx211 For The Treatment Of Diabetic Foot Osteomyelitis (DFO)

March 31 (Reuters) - Biomx Inc PHGE.A:

  • BIOMX ANNOUNCES POSITIVE TOPLINE RESULTS FROM PHASE 2 TRIAL EVALUATING BX211 FOR THE TREATMENT OF DIABETIC FOOT OSTEOMYELITIS (DFO)

  • BIOMX INC - BX211 FOUND TO BE SAFE AND WELL-TOLERATED

  • BIOMX INC -PLANNING FOR A PHASE 2/3 TRIAL OF BX211, PENDING U.S. FOOD AND DRUG ADMINISTRATION (FDA) FEEDBACK

Source text: ID:nGNX1VmHGn

Further company coverage: PHGE.A

((Reuters.Briefs@thomsonreuters.com;))

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10